ClinConnect ClinConnect Logo
Search / Trial NCT00005095

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Launched by NORTHWESTERN UNIVERSITY · Jan 26, 2003

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Ovarian Epithelial Cancer Hereditary Breast/Ovarian Cancer (Brca1, Brca2) Fallopian Tube Cancer Ovarian Germ Cell Tumor Ovarian Sarcoma Ovarian Stromal Cancer Endometrial Cancer Uterine Sarcoma Vaginal Cancer Cervical Cancer Vulvar Cancer Uterine Leiomyomata

ClinConnect Summary

This clinical trial is focused on improving the early detection and prevention of ovarian cancer, particularly for women who are at higher risk. The study is collecting blood samples and health information to help researchers develop better methods for identifying ovarian cancer at its earliest stages. If you're a woman between 18 and 80 years old and have a family history of ovarian or related cancers, or if you're undergoing surgery for a gynecological issue, you might be eligible to participate in this study.

Participants can expect to provide some health information and samples, which will contribute to important research aimed at preventing ovarian cancer. The trial is currently recruiting, so if you're interested, you may want to discuss this opportunity with your healthcare provider. This research is crucial as it aims to help find better ways to identify and potentially prevent ovarian cancer, making it an important step for women's health.

Gender

FEMALE

Eligibility criteria

  • DISEASE CHARACTERISTICS:
  • * Meets one of the following criteria:
  • * Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:
  • Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer
  • Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor
  • A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer
  • Increased risk as deemed by a certified genetic counselor
  • * Undergoing surgery for a gynecologic condition, including any of the following:
  • Diagnosis of a reproductive cancer
  • Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)
  • Highly suspicious adnexal mass
  • Risk-reducing prophylactic oophorectomy
  • PATIENT CHARACTERISTICS:
  • Age
  • Between the ages of 18 and 80

About Northwestern University

Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.

Locations

Chicago, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Lee P. Shulman, MD

Study Chair

Robert H. Lurie Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials